Welcome to our dedicated page for Astrazeneca Plc news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca Plc stock.
AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.
The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.
Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.
Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.
Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.
With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.
Compugen has announced that it will receive a $5 million milestone payment from AstraZeneca following the dosing of the first patient in the Phase 3 TROPION-Lung10 trial. This trial evaluates the efficacy and safety of rilvegostomig, a PD-1/TIGIT bispecific antibody, as monotherapy and in combination with datopotamab deruxtecan for first-line treatment of non-squamous non-small cell lung cancer patients with high PD-L1 expression. The trial is expected to enroll approximately 675 patients across 14 countries. This milestone is part of Compugen's strategy to expand its pipeline through partnerships, following a previous $10 million payment related to the ARTEMIDE-Biliary01 Phase 3 trial.
The TROPION-Lung01 phase 3 trial results indicate that datopotamab deruxtecan (Dato-DXd), developed by Daiichi Sankyo and AstraZeneca (AZN), shows a clinically meaningful improvement in overall survival (OS) for patients with nonsquamous non-small cell lung cancer (NSCLC) compared to docetaxel, the current standard chemotherapy.
Although the OS improvement did not reach statistical significance across all trial participants, it was notable in the pre-specified subgroup of nonsquamous NSCLC patients. The trial previously met its primary endpoint of progression-free survival (PFS), demonstrating a significant improvement in PFS and overall response rates compared to docetaxel.
The safety profile of Dato-DXd was favorable, with fewer dose reductions and no new safety concerns. These results support ongoing regulatory reviews in the U.S. and EU, aiming to establish Dato-DXd as a new standard treatment for advanced metastatic nonsquamous NSCLC.
AbelZeta Pharma, a clinical-stage biopharmaceutical company, has published an abstract of its C-CAR031 study for the ASCO 2024 Annual Meeting. The study focuses on hepatocellular carcinoma (HCC) and involves 24 patients. AbelZeta plans to present safety and preliminary efficacy data at the meeting in Chicago from May 31 to June 4, 2024. The oral presentation is scheduled for June 3, 2024, at 9:45 AM-11:15 AM CDT. More details can be found on the ASCO official website.
AstraZeneca and Alexion will present 14 studies on amyloidosis therapies at the 2024 International Symposium on Amyloidosis from May 26-30. Key presentations include new subgroup analyses for eplontersen, approved by the FDA in December 2023, and data on ALXN2220 and anselamimab in Phase III trials. The symposium will also feature real-world evidence and patient outcomes from various studies. AstraZeneca aims to advance the science of amyloidosis and improve patient outcomes. Important findings include the use of ALXN2220 for cardiac amyloid removal and the prevalence of phenotypes in ATTR amyloidosis. The company is also seeking regulatory approval for WAINUA in Europe.
Nona Biosciences announced a global license and option agreement with AstraZeneca for the development of monoclonal antibodies into targeted cancer therapies. Under this deal, Nona will receive $19 million initially, with potential milestone payments totaling up to $575 million, and tiered royalties on net sales. Nona may also receive additional payments if AstraZeneca exercises further options. This partnership leverages Nona's antibody discovery platform alongside AstraZeneca's expertise in oncology.
AstraZeneca is set to present new data from its oncology portfolio at the ASCO 2024 Annual Meeting.
Key highlights include results from the LAURA and ADRIATIC Phase III trials of TAGRISSO® (osimertinib) and IMFINZI® (durvalumab) for early lung cancer.
The DESTINY-Breast06 trial will showcase ENHERTU® (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low breast cancer.
Other notable presentations include data on novel therapies like C-CAR031 and updates from I-SPY2.2 Phase II trials.
This reinforces AstraZeneca's commitment to transforming cancer treatment across various stages and types.
AstraZeneca aims to reach $80 billion in total revenue by 2030, up from $45.8 billion in 2023. This growth will be driven by significant expansions in existing oncology, biopharmaceuticals, and rare disease portfolios, alongside the introduction of 20 new medicines by 2030. The company plans to continue investing in transformative technologies for sustained growth beyond 2030. AstraZeneca also targets a mid-30s percentage core operating margin by 2026, with further evolution expected post-2026. Additionally, the company aims to decouple carbon emissions from revenue growth, achieving carbon zero for Scope 1 and 2 emissions by 2026 and halving Scope 3 emissions by 2030.
New data from the Phase IIa COURSE trial suggests TEZSPIRE (tezepelumab) may reduce COPD exacerbations. The trial, involving 337 patients, showed a 17% reduction in annual COPD exacerbation rates compared to placebo, which was not statistically significant. However, in patients with blood eosinophil counts (BEC) ≥150 cells/µL, a significant 37% reduction was noted. For BEC ≥300 cells/µL, the reduction was 46%. Improvements in lung function and quality of life were also reported. Safety profiles were consistent with TEZSPIRE’s use in severe asthma. AstraZeneca and Amgen are planning Phase III trials based on these promising results.
AstraZeneca's CALQUENCE in combination with standard-of-care chemoimmunotherapy demonstrated a significant improvement in progression-free survival in mantle cell lymphoma patients. The trial also showed a favorable trend in overall survival, potentially extending patient survival. The safety profile of CALQUENCE remains consistent with known data, with no new safety concerns identified. The positive results from the ECHO Phase III trial could set a new standard of care for mantle cell lymphoma patients, transforming treatment outcomes earlier in the disease course.
AstraZeneca presents new data for TEZSPIRE and BREZTRI at ATS 2024 focusing on innovative treatments for COPD, severe asthma, and other respiratory diseases. Key highlights include the COURSE Phase IIa trial investigating tezepelumab in COPD patients and the potential of BREZTRI to reduce cardiopulmonary risk in COPD. The PR also covers advancements in asthma treatment, early pipeline science, and real-world evidence in COPD and asthma patients.
FAQ
What is the current stock price of Astrazeneca Plc (AZN)?
What is the market cap of Astrazeneca Plc (AZN)?
What is AstraZeneca PLC?
What therapeutic areas does AstraZeneca focus on?
Where does AstraZeneca generate most of its revenue?
What is the recent collaboration between AstraZeneca and Nona Biosciences about?
What is C-CAR031?
What is rilvegostomig?
What are some of AstraZeneca’s key recent achievements?
Where is AstraZeneca headquartered?
When was AstraZeneca formed?
What is the focus of AstraZeneca’s research and development?
